Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.

Uložené v:
Podrobná bibliografia
Vydané v:The New England journal of medicine Ročník 383; číslo 15; s. 1413 - 1424
Hlavní autori: Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Massachusetts Medical Society 08.10.2020
Predmet:
Aged
Antidiabetics
Benzhydryl Compounds - adverse effects
Benzhydryl Compounds - therapeutic use
Cardiology and cardiovascular system
Cardiovascular diseases
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Congestive heart failure
Death
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - complications
Disease Progression
Double-Blind Method
Drug dosages
Ejection fraction
Female
Genital tract
Glomerular filtration rate
Glomerular Filtration Rate - drug effects
Glucosides - adverse effects
Glucosides - therapeutic use
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - physiopathology
Hospitalization
Hospitalization - statistics & numerical data
Human health and pathology
Humans
Kidney diseases
Life Sciences
Male
Middle Aged
Peptides
Proportional Hazards Models
Quality of life
Renal Insufficiency, Chronic - complications
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Statistical analysis
Stroke Volume
ISSN:0028-4793, 1533-4406, 1533-4406
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2022190